Simvastatin Tablets

Pfizer Inc

Revision date : 2010-07-15

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating 1
Safety risk rating 1
Environmental risk rating 1

Note: Ingredients listed on restricted chemical lists

EC/CAS

9004-34-6

Name of the chemical

cellulose

Concentration

N/A

EC/CAS

9005-25-8

Name of the chemical

Starch

Concentration

N/A

EC/CAS

25013-16-5

Name of the chemical

tert.-Butylhydroxyanisole (BHA); tert-butyl-4-methoxyphenol

Concentration

N/A

EC/CAS

50-81-7

Name of the chemical

Ascorbic acid C6H8O6

Concentration

N/A

EC/CAS

232-679-6

Name of the chemical

Starch

Concentration

N/A

EC/CAS

246-563-8

Name of the chemical

tert.-Butylhydroxyanisole (BHA); tert-butyl-4-methoxyphenol

Concentration

N/A

Listed in

EC/CAS

209-150-3

Name of the chemical

Aluminium, zinc, magnesium and calcium stearates

Concentration

N/A

EC/CAS

200-066-2

Name of the chemical

Ascorbic acid C6H8O6

Concentration

N/A

General Information

Revision date

2010-07-15

Product name

Simvastatin Tablets

Chemical name

HMG-CoA reductase inhibitor; Statin

Emergency telephone

(24 hours) 1-800-424-9300

Icons in SDS

Company Information

company name

Pfizer Inc

e-mail address of the competent person responsible for the Safety Data Sheet

pfizer-MSDS@pfizer.com

Section 2

SECTION 2: Hazards identification

Appearance: White film-coated tablets

Hazard statements

Non-hazardous in accordance with international standards for workplace safety.

Additional information

Short Term: May cause eye irritation (based on components) . Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver Known Clinical Effects: Adverse effects associated with therapeutic use include respiratory infection abdominal pain, constipation, nausea. Clinical use of this drug has caused changes in liver function, muscle pain, and. weakness. EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.